Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer.
Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer. Oncol Lett. 2020 Apr;19(4):3189-3196 Authors: Chen JM, Chiu SC, Chen KC, Huang YJ, Liao YA, Yu CR Abstract Enolase transforms 2-phospho-D-glycerate into phosphoenolpyruvate during glycolysis. The human enolase (ENO) family comprises three members named ENO3, which is restricted to muscle tissues, ENO2, which is neuron- and neuroendocrine tissue-specific, and ENO1, which is expressed in almost all tissues. ENO1 is involved in various types of human cancer, including retinoblastoma, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, cholangiocarcinoma and gastric cancer. Furthermore, ENO1 enhances cell transformation in numerous cancer cell lines. It has been reported that ENO1 is involved in various activities that are detrimental to cell transformation, including apoptosis and differentiation. However, a few studies demonstrated that ENO1 can be down- or upregulated in various types of lung cancer, which suggests that ENO1 has an ambiguous role in the development of lung cancer. The present study aimed to investigate the differential influences of ENO1 on various types of cancer, and to clarify the role of ENO1 in lung cancer in particular. Western blotting was performed to assess ENO1 protein expression levels in lung cancer and esophageal cancer tissues. Furthermore, exogenous ENO1 was overexpressed in cell lines derived from various ...
CONCLUSIONS: Simultaneous CRC and CRLM resections seem to be safe when patients are carefully selected, also considering the risk of recurrence concerning oncologic outcomes. The pre-planning of simultaneous resection is mandatory to plan trocar positioning, procedure sequencing, and patient position. PMID: 32490901 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Ben Newland, Carmine Varricchio, Yvonne Körner, Franziska Hoppe, Christian Taplan, Heike Newland, Dimitri Eigel, Giusy Tornillo, Dagmar Pette, Andrea Brancale, Petra B. Welzel, F. Philipp Seib, Carsten Werner
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhuodong Chai, Chao Teng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han, Lifang Yin
CONCLUSION: a Navigation Program was developed adapted to the Brazilian reality, and attributions of the navigators were created. PMID: 32491120 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Houhe Liu, Yusi Quan, Xinlin Jiang, Xiaotian Zhao, Yi Zhou, Jijun Fu, Lingran Du, Xiaoya Zhao, Jing Zhao, Lu Liang, Di Yi, Yugang Huang, Guodong Ye
Publication date: Available online 3 June 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Hui-Min Wang, Ai-Jun Wang, Pei-Xin Yuan, Jiu-Ju Feng
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC03589K, CommunicationLongbing Ling, Haizhou Yu, Muhammad Ismail, Yan-Ping Zhu, Yuan Du, Junhui Qi An amphiphilic dimeric-podophyllotoxin (PODO) phospholipid was synthesized to assemble into liposomes as a combination of prodrug and nanocarriers. Results have demonstrated cell membrane-like delivery system possessed an improved cellular uptake... The content of this RSS Feed (c) The Royal Society of Chemistry
Authors: Cheng J, Yang A, Cheng S, Feng L, Wu X, Lu X, Zu M, Cui J, Yu H, Zou L Abstract BACKGROUND MicroRNAs (miRNAs) are attracting substantial interest as promising noninvasive biomarkers for gastric cancer (GC). Our study aimed to identify circulating miRNAs that are potential noninvasive markers for precancerous lesions and early gastric cancers (EGCs). MATERIAL AND METHODS Plasma specimens were obtained from 58 gastritis subjects, 54 patients with precancerous lesions, and 38 EGC patients for study. RESULTS Significant differences in the plasma expression levels of miR-19a-3p, miR-22-3p, miR-146a-5p, and miR-483-5p (all P
For example, does transporting patients with cancer from Site A to Site B count as clinical volunteer experience? This is assuming that the driver is in direct contact with the patients. What are some other examples of gaining clinical exposure that are unheard/unrealized of? This will greatly help students such as myself in their gap-years working in non-clinical jobs needing to gain more volunteer experience! For my particular case, I am seeking for an opportunity to gain ~80 hours... What are Some Examples of NonTraditional Ways of Earning Clinical Volunteer Experience?
Renal angiomyolipoma (AML) is the most common benign solid renal neoplasm seen in daily clinical practice, with an estimated prevalence of 0.2% to 0.6%.1 It is a triphasic mesenchymal neoplasm composed of varying amounts of dysmorphic vasculature, smooth muscle, and mature adipocytes. Pathologically, AML is now considered among the family of perivascular epithelioid cell tumors. Approximately 80% of cases are sporadic, with mean age at presentation being 43 years and most cases identified at fourth to sixth decades of life. There is also a strong female predilection, with female-to-male ratio of 4:1 in sporadic cases.1 Twe...
More News: Bile Duct Cancer | Brain | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Esophagus Cancer | Eye Cancers | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Lung Cancer | Neurology | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Retinoblastoma | Study